High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients
- Author:
Adriano PELLICELLI
1
;
Vincenzo MESSINA
;
Valerio GIANNELLI
;
Marco DISTEFANO
;
Valeria Pace PALITTI
;
Pascal VIGNALLY
;
Pierluigi TARQUINI
;
Antonio IZZI
;
Alessandra MORETTI
;
Sergio BABUDIERI
;
Serena DELL’ISOLA
;
Massimo MARIGNANI
;
Gaetano SCIFO
;
Vincenzo IOVINELLA
;
Giuseppe CARITI
;
Maurizio POMPILI
;
Francesco Di CANDILO
;
Luca FONTANELLA
;
Giuseppe M. ETTORRE
;
Giovanni VENNARECCI
;
Antonio Massimo IPPOLITO
;
Giorgio BARBARINI
Author Information
- Publication Type:ORiginal Article
- From:Gut and Liver 2020;14(3):357-367
- CountryRepublic of Korea
- Language:0
-
Abstract:
Background/Aims:Patients with genotype 3 hepatitis C virus (G3-HCV) cirrhosis are very difficult to treat compared to patients with other HCV genotypes. The optimal treatment duration and drug regimen associated with ribavirin (RBV) remain unclear. To evaluate the efficacy and safety of daclatasvir (DCV)/sofosbuvir (SOF) plus a flat dose of 800 mg RBV (flat dose) compared to DCV/SOF without RBV or DCV/SOF plus an RBV dose based on body weight (weight-based) in G3-HCV patients with compensated or decompensated cirrhosis.
Methods:We analyzed data for 233 G3 cirrhotic patients. Of these, 70 (30%), 87(37%) and 76 (33%) received SOF/DCV, SOF/DCV/RBV flat dose, and SOF/DCV/RBV weight-based dose, respectively. Treatment duration was 24 weeks. Sustained virological response (SVR) was evaluated at week 12 posttreatment (SVR12).
Results:Overall, SVR12 was achieved in 220 out of 233 patients (94.4%). The SVR12 rate was lower in the DCV/SOF group than in the DCV/SOF/RBV flat-dose group and the DCV/SOF/RBV weight-based group (87.1% vs 97.7% and 97.4%, respectively, p=0.007). A higher incidence of anemia occurred in the DCV/SOF/RBV weight-based group compared to those in the other two groups (p<0.007).
Conclusions:We found that the DCV/SOF/RBV flat-dose regimen is an effective treatment in terms of efficacy and safety in patients with G3-HCV compensated or decompensated cirrhosis. Therefore, antiviral regimens without RBV should be restricted only to naïve patients with G3-HCV compensated cirrhosis who have a clear contraindication for RBV.
